Meet Elaine DeLack, CEO and Founder of MedDev inc.,
Developer of Respen-A™
(reprint of most popular post of 2019)
I have been told, many times, that I take a different approach to science and developing a treatment. I actually test everything first on myself. I suppose this comes from my history of being diagnosed with multiple sclerosis (MS), and needing to find something to help myself as traditional medicine had nothing to offer of benefit. Once I have thoroughly researched something, I test it first on myself, and then on the next willing guinea pig- who has been my husband. This was how Respen-A™ came to be used in bipolar disorder, then depression, then anxiety, then autism, then ADD/ADHD, and even cancer.
No, my husband didn’t have all of these conditions, but he was bipolar, often suffered from depression and anxiety, and had a very volatile temper. He could be whistling happily, and then the next minute throwing things and swearing. This could happen several times within an hour. A nebulous stimulus could set him off- so we walked on eggshells around him, not knowing what might trigger a rage. Although he only drank on occasion, when he did drink, he couldn’t stop after just a couple of beers- he would drink until he was inebriated. He volunteered to try the Respen-A™ to see if it would mellow his mood swings, and it did, immediately that same day.
Seeing how well it resolved my husband's symptoms, it was decided to study Respen-A™ in a double blind, placebo controlled crossover study in patients that had major depressive disorder. Most of the patients were resistant to treatment with antidepressants. Based on the results that my husband had seen with the Respen-A™, but being only one patient (an N of 1), the statistician predicted that we needed a minimum of 40 people in the study in order for the study to have power- meaning that a noticeable effect would be statistically identified if the Respen-A™ was effective in treating the symptoms of depression.
Most pharmaceuticals are first tested in a very homogenous group in which the participants are “cherry picked”, excluding any subjects that may have other conditions that would diminish the likelihood of them showing a favorable effect of the drug being tested. These homogenous studies are then followed by several more studies carefully broadening the selection of participants. Due to our limited financial resources to fund studies, we chose a very heterogeneous group of participants for our pilot study- might as well find out right away if Respen-A™ had a robust enough effect to show statistical significance at the get go. We included participants that would have been excluded from any antidepressant drug study, such as participants with fibromyalgia, rheumatoid arthritis, lupus, and even cirrhosis of the liver due to alcoholism.
Due to funding constraints, we decided to close the study with only having 21 patients enrolled, because we had already expended the funds we had budgeted for participant recruitment. Despite the heterogeneous study population, and only 21 participants, Respen-A™ showed a very robust effect with a p value of 0.001 (a p value of 0.05 or less is considered a significant effect).
The Respen-A™ depression study showed that Respen-A™ also showed significant effect in treating the symptoms of anxiety as measured by the Profile of Moods (POMS) testing done in the study. Thus, my granddaughter, who frequently suffers anxiety and facial/eye tics, started using the Respen-A™ when those symptoms arose, and within minutes of applying the Respen-A™ disc, her symptoms resolved.
I was watching my granddaughter play in a basketball tournament one day, and noticed that she was displaying some facial tics, and that her attentiveness in the game was not her usual. She seemed to be running around the court unaware of the position she was supposed to be playing, and she was becoming very frustrated. I discovered that she was not wearing the Respen-A™ disc during the game. So, before her next game I applied the Respen-A™ disc, and her performance in the game took a 180 degree turn. Her concentration and performance in the game improved so much that parents of her teammates commented, and wanted to know what had changed. Interestingly, one of the parents pursued getting the Respen-A™ for their daughter who struggled in school and on the basketball court due to ADD. Their daughter, too saw impressive improvement in her basketball skills and school performance.
Some may wonder how Respen-A™ can show benefit for so many different health conditions? This is because all of these conditions have been shown to have a common mitochondrial dysfunction—deficient MAO-A activity. Respen-A™ is a homeopathic dilution of Reserpine, which has been shown to double the activity of MAO-A.